Prognostic factors for survival in patients with resectable advanced gastric adenocarcinoma
| Autor: | Marisol Luna-Castillo, Luis Enrique García-Ríos, Rafael Medrano-Guzmán, Daniel Valencia-Mercado, Domingo González-Rodríguez |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Ocean Engineering Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Gastrectomy Risk Factors Stomach Neoplasms Weight loss medicine Humans Lymph node Survival analysis Aged Neoplasm Staging Retrospective Studies business.industry Age Factors Cancer Retrospective cohort study Middle Aged Prognosis medicine.disease Survival Analysis Surgery medicine.anatomical_structure Lymphatic Metastasis 030220 oncology & carcinogenesis Cohort Lymph Node Excision Female 030211 gastroenterology & hepatology Neoplasm Recurrence Local Symptom Assessment medicine.symptom business |
| Zdroj: | Cirugía y Cirujanos (English Edition). 84:469-476 |
| ISSN: | 2444-0507 |
| DOI: | 10.1016/j.circen.2016.11.009 |
| Popis: | Background Patients under 45 years with gastric cancer are associated with a poor prognosis. Recent studies report that the 5-year survival is better in younger patients after curative resection. Objective To determine if prognostic factors such as age under 45 years old, anaemia, weight loss, tumour differentiation, histological sub-type, depth of invasion, and lymph node involvement, reduce the survival of patients with resectable advanced gastric adenocarcinoma undergoing gastrectomy with limited and extended lymphadenectomy. Materials and methods This study included a cohort of consecutive cases treated in the Sarcomas Department of the Oncology Hospital of the Centro Medico Nacional Siglo XXI, of the Instituto Mexicano del Seguro Social, during the period between January 2000 and December 2006. Results Of the total of 588 patients evaluated, 112 (19%) were under 45 years, 43% classified as Borrmann IV, and 36% as Borrmann III. Metastatic disease was present in 39.3%, localised diffuse in 12.5%; lower resectability 52.7 vs. 61.3% in older than 45 years. At the end of the study 29.5% of patients under 45 years were alive; no recurrence in 26.8%, with an overall survival of 58.6±4.3 months, compared with 18.3% of patients alive over 45 years, 17.9% disease-free, and with overall survival 35.2±4.3 months resectable disease. Conclusions Patients under 45 years have a better survival after a two-year disease-free period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|